Masseter Myofascial Pain Relief Following an Intra-muscular Injection With Botulinum Toxin Type A.

Launched by REGION ÖREBRO COUNTY · Jun 8, 2020

Keywords

ClinConnect Summary

Temporomandibular disorders (TMD) is the second most common musculoskeletal condition (after chronic low back pain) and refer to pain and dysfunction in the temporomandibular system and its muscles, joints, and associated structures. The prevalence of TMD is 4-15% among adults where myalgia is the most common form of TMD.

Diagnostic Criteria for temporomandibular disorders (DC/TMD) was introduced in 2014 and is used worldwide for classifying TMD. Myalgia is the second group of disorders of DC/TMD and is defined by pain in a masticatory structure that is modified by jaw movement, function, ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age \> 18 years
• • \> 3-month complaints of jaw/face pain
• • the diagnose myalgia according to DC/TMD
• • understands Swedish verbally and in writing
• • in writing give his/her consent to participate
• Exclusion Criteria:
• • polyarthritis/connective tissue disease
• • fibromyalgia or other generalized pain
• • neurological disorders
• • whiplash associated disorders
• • ongoing virus or bacterial infection
• • ongoing dental treatment
• • botulinum toxin injection in the jaw or face past six months
• • complex psychiatric/psychological profile, institutional residence
• • employee at the trial clinic, internal resident
• • hypersensitivity to botulinum toxin, human albumin
• • serious health conditions according to the examiner's assessment
• • in the presence of infection at the proposed injection site(s)
• • pregnancy or lactating
• • fertile women not on contraception